相似文献
1
Proton MR spectroscopy in metabolic assessment of musculoskeletal lesions.
AJR Am J Roentgenol. 2012 Jan;198(1):162-72. doi: 10.2214/AJR.11.6505.
2
Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
Clin Imaging. 2010 Jan-Feb;34(1):47-52. doi: 10.1016/j.clinimag.2009.03.013.
3
Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy.
AJR Am J Roentgenol. 2007 Jun;188(6):1513-20. doi: 10.2214/AJR.06.0935.
4
A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T.
AJR Am J Roentgenol. 2010 Jul;195(1):W69-75. doi: 10.2214/AJR.09.3718.
5
Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques.
Radiology. 2012 Nov;265(2):340-56. doi: 10.1148/radiol.12111740.
6
Molecular characterization of musculoskeletal tumors by proton MR spectroscopy.
Semin Musculoskelet Radiol. 2007 Sep;11(3):240-5. doi: 10.1055/s-2008-1038313.
7
[Imaging of musculoskeletal tumors : what are new MR techniques capable of and what is included in an optimal MR protocol?].
Radiologe. 2013 May;53(5):396-8. doi: 10.1007/s00117-013-2503-8.
8
In vivo proton spectroscopy of giant cell tumor of the bone.
AJR Am J Roentgenol. 2008 Feb;190(2):W133-9. doi: 10.2214/AJR.07.2802.
9
Qualitative 3-T Proton MR Spectroscopy for the Characterization of Musculoskeletal Neoplasms: Update on Diagnostic Performance and Indications.
AJR Am J Roentgenol. 2017 Jun;208(6):1312-1319. doi: 10.2214/AJR.16.17285. Epub 2017 Mar 16.
10
Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results.
Radiology. 2004 Aug;232(2):599-605. doi: 10.1148/radiol.2322031441.
引用本文的文献
1
Investigating the associations between lumbar paraspinal muscle health and age, BMI, sex, physical activity, and back pain using an automated computer-vision model: a UK Biobank study.
Spine J. 2024 Jul;24(7):1253-1266. doi: 10.1016/j.spinee.2024.02.013. Epub 2024 Feb 28.
2
State of the art in the diagnostic evaluation of osteomyelitis: exploring the role of advanced MRI sequences-a narrative review.
Quant Imaging Med Surg. 2024 Jan 3;14(1):1070-1085. doi: 10.21037/qims-23-1138. Epub 2024 Jan 2.
3
Tumor cellularity beyond the visible in soft tissue sarcomas: Results of an ADC-based, single center, and preliminary radiomics study.
Front Oncol. 2022 Oct 11;12:879553. doi: 10.3389/fonc.2022.879553. eCollection 2022.
4
Characterization of lipomatous tumors with high-resolution H MRS at 17.6T: Do benign lipomas, atypical lipomatous tumors and liposarcomas have a distinct metabolic signature?
Front Oncol. 2022 Sep 9;12:920560. doi: 10.3389/fonc.2022.920560. eCollection 2022.
5
Comparing the blood oxygen level-dependent fluctuation power of benign and malignant musculoskeletal tumors using functional magnetic resonance imaging.
Front Oncol. 2022 Aug 12;12:794555. doi: 10.3389/fonc.2022.794555. eCollection 2022.
6
Current progress and future trends in imaging of musculoskeletal bone tumours.
J Clin Orthop Trauma. 2021 Oct 7;23:101622. doi: 10.1016/j.jcot.2021.101622. eCollection 2021 Dec.
7
Correlation of quantitative diffusion weighted MR imaging between benign, malignant chondrogenic and malignant non-chondrogenic bone tumors with histopathologic type.
Heliyon. 2021 Mar 8;7(3):e06402. doi: 10.1016/j.heliyon.2021.e06402. eCollection 2021 Mar.
8
MRI in the assessment of adipose tissues and muscle composition: how to use it.
Quant Imaging Med Surg. 2020 Aug;10(8):1636-1649. doi: 10.21037/qims.2020.02.06.
9
Characterisation of musculoskeletal tumours by multivoxel proton MR spectroscopy.
Skeletal Radiol. 2017 Apr;46(4):483-495. doi: 10.1007/s00256-017-2573-1. Epub 2017 Feb 11.
10
How Can New Imaging Modalities Help in the Practice of Radiology?
Eurasian J Med. 2016 Oct;48(3):213-221. doi: 10.5152/eajm.2016.0260.
本文引用的文献
1
MR spectroscopy and spectroscopic imaging of the brain.
Methods Mol Biol. 2011;711:203-26. doi: 10.1007/978-1-61737-992-5_9.
2
Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection.
Eur J Radiol. 2012 Mar;81(3):411-6. doi: 10.1016/j.ejrad.2010.12.017. Epub 2011 Jan 6.
3
Quantitation of normal metabolite concentrations in six brain regions by in-vivoH-MR spectroscopy.
J Med Phys. 2010 Jul;35(3):154-63. doi: 10.4103/0971-6203.62128.
4
Comparison of 3.0 T proton magnetic resonance spectroscopy short and long echo-time measures of intramyocellular lipids in obese and normal-weight women.
J Magn Reson Imaging. 2010 Aug;32(2):388-93. doi: 10.1002/jmri.22226.
5
A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T.
AJR Am J Roentgenol. 2010 Jul;195(1):W69-75. doi: 10.2214/AJR.09.3718.
6
Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
Clin Imaging. 2010 Jan-Feb;34(1):47-52. doi: 10.1016/j.clinimag.2009.03.013.
7
Quantification of muscle choline concentrations by proton MR spectroscopy at 3 T: technical feasibility.
AJR Am J Roentgenol. 2010 Jan;194(1):W73-9. doi: 10.2214/AJR.09.3125.
8
Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast.
Magn Reson Med. 2009 Jun;61(6):1286-92. doi: 10.1002/mrm.21937.
9
Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
J Comput Assist Tomogr. 2008 Nov-Dec;32(6):987-94. doi: 10.1097/RCT.0b013e31815b9ce9.
10
Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
Chin Med J (Engl). 2009 Jan 5;122(1):39-43.
Zotero 插件